Figure 1 | Scientific Reports

Figure 1

From: Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine

Figure 1

Antibodies against influenza virus and SARS-CoV-2. Female BALB/c mice were immunized subcutaneously with Co WPV, Flu WPV, Co/Flu WPV, or PBS as the control group, and sample collection and virus challenge experiments were conducted (n = 5/group; (a). Sera were collected at 19 days post-vaccination for measurement of hemagglutination inhibition (HI) antibody titers (b) and neutralizing antibodies against A/California/07/2009 (X-179A)(H1N1) [A/California (H1N1)] (c) and SARS-CoV-2 WK-521 (Ancestral strain) (d). Mean and SD are shown. Statistical analysis was performed using Kruskal–Wallis test with Dunn’s multiple comparisons tests. **p < 0.01.

Back to article page